{"id":34924,"date":"2020-11-11T12:08:13","date_gmt":"2020-11-11T12:08:13","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=34924"},"modified":"2021-03-18T12:11:25","modified_gmt":"2021-03-18T12:11:25","slug":"yong-jie-lu","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/","title":{"rendered":"Yong-Jie Lu"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Yong-Jie Lu MD, PhD<\/h2>\n<h4>Professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London<\/h4>\n\t<div class=\"su-expand su-expand-collapsed su-expand-link-style-default\" data-height=\"400\"><div class=\"su-expand-content su-u-trim\" style=\"color:#333333;max-height:400px;overflow:hidden\">\n<p>Professor Yong-Jie Lu completed his medical training and PhD in China. He did his postdoctoral studies 1995-2001 at Institute of Cancer Research, London, where he was promoted to a permanent post of senior staff scientist. In 2003, to set up his own research team for male urological cancer genetic and biomarker studies at Barts Cancer institute, Queen Mary University of London, where he was promoted subsequently to reader and professor.<\/p>\n<p>He is currently honorable professor in Second Military Medical University, Shanghai, China; Naning Medical University; Chongqing Medical University; and Zhengzhou University Medical College. He has been led the Chinese prostate cancer genetic risk study collaborative group (CHIPGENCS) since 2010 and is a member of prostate cancer International Cancer Genome Consortium (ICGC) and prostate cancer genetic risk study international consortium (PRACTICAL).<\/p>\n<p>The mission of his research team is to reduce motility and morbidity of patients with male urological cancers by facilitating precision medicine through the identification of biomarkers and therapeutic targets and the development\/application of novel approaches in biomarker analysis and cancer therapy.<\/p>\n<p>His past work has been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, his research work moved into circulating biomarker development, in particular in the area of circulating tumour cells in prostate cancer, aiming to translate them into cancer diagnosis, prognosis and therapeutic stratification.<\/p>\n<p>He published more than 100 peer reviewed original studies, in journals including Lancet, Nature Genetics, PNAS, Journal Clinical Oncology, Cancer Research and Clinical Cancer Research. He also published several review articles and book chapters.<\/p>\n<p>His CTC study finding has been highlighted in dozens of national and international media both in November 2016 and recently (September 2019). His finding in circulating cell biomarkers has been reported as research news in multiple national and international media, including TV, radio, newspaper and online news media in July 2017. He has filled two patent applications for prostate cancer prognosis using circulating cell biomarkers. He has been serving as editorial board members for a number of international scientific journals.<\/p>\n<\/div><div class=\"su-expand-link su-expand-link-more\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show more<\/span><\/a><\/div><div class=\"su-expand-link su-expand-link-less\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show less<\/span><\/a><\/div><\/div>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2.jpg\" alt=\"Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-315&#215;470.jpg 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Circulating biomarkers for cancer diagnosis and precision medicine \n\t<\/h3>\n\t<ul>\n<li>Circulating tumour biomarker has great potential in cancer diagnosis and precision medicine<\/li>\n<li>CTCs are valuable for cancer diagnosis, treatment prediction\/monitoring<\/li>\n<li>Looking out for other undiscovered biomarkers in liquid biopsy<\/li>\n<\/ul>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.qmul.ac.uk\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.qmul.ac.uk\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/yong-jie-lu-14109040\/\" target=\"_blank\" rel=\"noopener noreferrer\">Visit Profile<\/a><\/p>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Yong-Jie Lu MD, PhD Professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London<\/p>\n","protected":false},"author":1,"featured_media":33302,"parent":34845,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-34924","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Yong-Jie Lu &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Professor Yong-Jie Lu completed his medical training and PhD in China. He did his postdoctoral studies 1995-2001 at Institute of Cancer Research, London\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yong-Jie Lu &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Professor Yong-Jie Lu completed his medical training and PhD in China. He did his postdoctoral studies 1995-2001 at Institute of Cancer Research, London\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T12:11:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/\",\"name\":\"Yong-Jie Lu &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg\",\"datePublished\":\"2020-11-11T12:08:13+00:00\",\"dateModified\":\"2021-03-18T12:11:25+00:00\",\"description\":\"Professor Yong-Jie Lu completed his medical training and PhD in China. He did his postdoctoral studies 1995-2001 at Institute of Cancer Research, London\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CDx\/Biomarkers &#038; Biobanking 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Yong-Jie Lu\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yong-Jie Lu &#8226; BioTech Pharma Summit","description":"Professor Yong-Jie Lu completed his medical training and PhD in China. He did his postdoctoral studies 1995-2001 at Institute of Cancer Research, London","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/","og_locale":"en_US","og_type":"article","og_title":"Yong-Jie Lu &#8226; BioTech Pharma Summit","og_description":"Professor Yong-Jie Lu completed his medical training and PhD in China. He did his postdoctoral studies 1995-2001 at Institute of Cancer Research, London","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T12:11:25+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/","name":"Yong-Jie Lu &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg","datePublished":"2020-11-11T12:08:13+00:00","dateModified":"2021-03-18T12:11:25+00:00","description":"Professor Yong-Jie Lu completed his medical training and PhD in China. He did his postdoctoral studies 1995-2001 at Institute of Cancer Research, London","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/yong-jie-lu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"CDx\/Biomarkers &#038; Biobanking 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/cdx-biomarkers-biobanking-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Yong-Jie Lu"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=34924"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34924\/revisions"}],"predecessor-version":[{"id":36045,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34924\/revisions\/36045"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33302"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=34924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}